Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.
about
The spectrum of disease in chronic traumatic encephalopathyTau fragmentation, aggregation and clearance: the dual role of lysosomal processingUnified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapyNeuroimaging assessment of early and late neurobiological sequelae of traumatic brain injury: implications for CTEDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targetsTau clearance mechanisms and their possible role in the pathogenesis of Alzheimer diseaseTangles, Toxicity, and Tau Secretion in AD - New Approaches to a Vexing ProblemTau-targeted treatment strategies in Alzheimer's diseaseThe release and trans-synaptic transmission of Tau via exosomesThe effect of a DeltaK280 mutation on the unfolded state of a microtubule-binding repeat in TauIntrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau FragmentationIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesCytoskeletal pathologies of Alzheimer diseaseTau-dependent microtubule disassembly initiated by prefibrillar beta-amyloidFTDP-17 mutations in Tau alter the regulation of microtubule dynamics: an "alternative core" model for normal and pathological Tau action.Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesHirano bodies differentially modulate cell death induced by tau and the amyloid precursor protein intracellular domain.Amyloid-like aggregates of neuronal tau induced by formaldehyde promote apoptosis of neuronal cellsTwo-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes.TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Targeting Abeta and tau in Alzheimer's disease, an early interim reportDiscovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.Why pleiotropic interventions are needed for Alzheimer's disease.Implicating calpain in tau-mediated toxicity in vivo.Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process.Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesPolymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles.The role of telomerase protein TERT in Alzheimer's disease and in tau-related pathology in vitro.Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation.Carnosine's effect on amyloid fibril formation and induced cytotoxicity of lysozyme.Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.Are tangles as toxic as they look?The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeuticsPro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulationAdvances in tau-based drug discovery.
P2860
Q22242925-48D33C6E-861E-4561-9C62-23D53E96B11EQ24656204-6A4AFA41-75E9-4217-9824-682DA575E22EQ26382049-8BD709C8-ED7E-4D6C-83AD-734D6800D36AQ26781672-B02C0AEA-9785-4DF3-B8E2-D67F644362B9Q26865654-2C73DC88-C4BD-4C4B-B4C1-24F3BC493FD9Q26995276-6725CFD9-C4F3-4402-8B49-4D540E25B07FQ27004724-0F1982A4-B7F3-41F4-B5F5-0C39DBDFAAF5Q27023429-D33FBFB0-E2B6-45BA-B36D-269B9D360185Q28468594-4409068A-AF2F-4B2C-96E3-ED6CB4803D77Q28473391-DA5E07F1-83D6-46F8-947B-9327042E021CQ28552366-16C70295-27DC-4B2D-91A4-CE4CBC39309FQ28597211-FA820C30-657E-4579-8EEA-99124E4278B1Q30435267-EF045D4A-E4A3-4B93-9780-7287F7711027Q30442116-56E9030B-AC56-46B1-AEC2-2948A362EB27Q30485126-DAABC3D5-CFFD-4B0D-8F40-FEB728A3AD37Q30502900-1A336B26-011F-482F-8228-BD8A17F8C054Q30649677-6461D051-4AFA-4709-AA43-F585D782DFBFQ30669674-1F0AB564-079C-4E73-85F6-F470EBE186D4Q31165645-DCA8F761-0D7F-42BB-A6C6-4CCE4EF90C70Q33269957-6E3B85FF-3C15-4841-B9D3-29B6489E1614Q33418581-042B50EE-B1FB-4203-B2E5-7967E8BEF8B4Q33749435-221E27C5-E843-4F0F-889B-8F6C49F7D407Q33828966-93AD8E3A-8110-4C02-AE56-B0378978D795Q33829008-901F73CC-4700-4915-9924-7F278DB26F1BQ33861802-245C0963-6226-4703-A369-E0ADBDC208B0Q33876128-2A7D5958-3461-415C-9857-8ECA8A639B51Q34000095-5145207D-B2A0-4663-993A-A7635C7AB7BFQ34020079-C8C210AB-8190-486E-9F64-F33084B9CC01Q34110227-667A7B90-F962-44F9-B176-45DA99064959Q34154643-D8CDEAD1-A94E-4D36-AEAA-BA7767E5748CQ34695519-73643EBE-97E2-44AE-BA0E-FF41C5864B04Q34869120-39C128F9-FE89-4603-8A60-59F61838B6DEQ35020283-1B21D4CC-3027-402B-A26D-E1474F0FFF91Q35063341-4D5F2D4B-D5E3-4FDC-8559-FAE5AFD28C16Q35069891-AEE2924E-12E9-47C4-9A28-3ED63CE5F93AQ35152946-73E5E88A-B3B9-46A7-8E68-EDC924B7027FQ35214319-60ADF9FD-A8BD-43AD-85FB-14DA8A029579Q35216140-F4958D89-67B3-49ED-9BCB-D9B17B6AA587Q35258352-FF5ACA23-AE9F-45A7-A985-DD4A0E3107F0Q35321539-9A6395C9-CB08-48C0-83BB-AC8E31F45D03
P2860
Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@ast
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@en
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@nl
type
label
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@ast
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@en
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@nl
prefLabel
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@ast
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@en
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@nl
P2093
P50
P356
P1476
Inducible expression of Tau re ...... e reversed by inhibitor drugs.
@en
P2093
Inna Khlistunova
Jacek Biernat
Marcus Pickhardt
Martin von Bergen
Yipeng Wang
P304
P356
10.1074/JBC.M507753200
P407
P577
2005-10-24T00:00:00Z